Butterfield Joseph H
Division of Allergic Diseases and Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, Minnesota, USA,
Int Arch Allergy Immunol. 2020;181(1):43-50. doi: 10.1159/000503964. Epub 2019 Nov 13.
Although 4 mast cell mediators can be routinely measured, the results of initial testing to evaluate symptoms of mast cell activation have not been widely reported.
We examined the results of mast cell mediator tests used to assess patients with mast cell activation symptoms during a 5-year time span.
After excluding patients with alternative diagnoses, records of 108 patients were reviewed for initial mediator test results. Mediators included serum tryptase plus urinary N-methyl histamine (N-MH), leukotriene (LT)E4, and 11β-prostaglandin (PG) F2α or 2,3-dinor-11β-PGF2α (BPG).
Most commonly, either a single measured elevation of 1 mediator (48.1%) or elevations of 2 (33.3%) mediators was found at baseline, during symptoms or at both time points. Elevated levels of a single mediator in order of frequency were: BPG > tryptase > LTE4 > N-MH, and for two mediators: BPG + tryptase (n = 16 cases) > BPG + LTE4 (n = 9) > BPG + N-MH (n = 6). Elevations in 3 mediators (n = 8) or 4 mediators (n = 2) were much less frequent. Monoclonal mast cell activation syndrome (n = 6), and systemic and cutaneous mastocytosis (n = 4) were also infrequent. Baseline plus symptom-associated tryptase values were obtained in only 7 patients.
This survey suggests that elevations of 1 or 2 mediators are the most common (total 81.4% of cases) findings from initial tests for mast cell activation. Elevated levels of BPG were most commonly found both singly and in combination with other mediators, followed by the finding of elevated levels of tryptase. Baseline plus symptom-associated tryptase levels were measured in only a minority of patients.
尽管可以常规检测4种肥大细胞介质,但用于评估肥大细胞活化症状的初始检测结果尚未得到广泛报道。
我们研究了在5年时间跨度内用于评估有肥大细胞活化症状患者的肥大细胞介质检测结果。
在排除有其他诊断的患者后,回顾了108例患者的初始介质检测结果记录。介质包括血清类胰蛋白酶加尿N-甲基组胺(N-MH)、白三烯(LT)E4、11β-前列腺素(PG)F2α或2,3-二去甲-11β-PGF2α(BPG)。
最常见的情况是,在基线、症状发作时或两个时间点均发现单一介质升高(48.1%)或两种介质升高(33.3%)。单一介质升高的频率依次为:BPG>类胰蛋白酶>白三烯E4>N-甲基组胺;两种介质升高的情况为:BPG+类胰蛋白酶(16例)>BPG+白三烯E4(9例)>BPG+N-甲基组胺(6例)。三种介质升高(8例)或四种介质升高(2例)的情况则少见得多。单克隆肥大细胞活化综合征(6例)以及系统性和皮肤肥大细胞增多症(4例)也较少见。仅7例患者获得了基线加症状相关的类胰蛋白酶值。
这项调查表明,1种或2种介质升高是肥大细胞活化初始检测中最常见的结果(共占病例的81.4%)。单独或与其他介质联合时,最常检测到BPG水平升高,其次是类胰蛋白酶水平升高。仅少数患者检测了基线加症状相关的类胰蛋白酶水平。